AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousHematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationLiver TransplantationTransplantation ConditioningStem Cell TransplantationMultiple MyelomaGraft SurvivalSurvival RateKidney TransplantationMelphalanTreatment OutcomeHematopoietic Stem Cell MobilizationCombined Modality TherapyPeripheral Blood Stem Cell TransplantationDisease-Free SurvivalCell TransplantationSurvival AnalysisHeart TransplantationLymphoma, Non-HodgkinSalvage TherapyLung TransplantationAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCell SurvivalBone Marrow PurgingRecurrenceCarmustineCyclophosphamideRetrospective StudiesRemission InductionGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorLeukapheresisWhole-Body IrradiationHematopoietic Stem CellsTime FactorsEtoposideOrgan TransplantationFollow-Up StudiesHodgkin DiseaseGraft RejectionBusulfanHematologic NeoplasmsImmunosuppressive AgentsBlood Transfusion, AutologousTissue DonorsCytarabinePancreas TransplantationIslets of Langerhans TransplantationTransplantationTransplantation ImmunologyPrognosisGraft vs Tumor EffectMyeloablative AgonistsThalidomideTransplantation ChimeraBone MarrowVincristineKanamycin KinaseCells, CulturedTransplantation, IsogeneicFeasibility StudiesSurvivalBlood Component RemovalNeoplasm, ResidualLymphomaPrednisoneLiving DonorsGenetic TherapyTransplantation, HeterotopicHematopoiesisCell SeparationProspective StudiesAntineoplastic Agents, AlkylatingCord Blood Stem Cell TransplantationIdarubicinLeukemia, Myeloid, AcuteBone Marrow CellsAntineoplastic AgentsLeukemiaStem CellsDexamethasoneMyelodysplastic SyndromesDoxorubicinHeart-Lung TransplantationColony-Forming Units AssayBlood Cell CountNeoplasm Recurrence, LocalImmunosuppressionImmunomagnetic SeparationAntibodies, MonoclonalMultivariate AnalysisCell Culture TechniquesTissue and Organ ProcurementAntibodies, Monoclonal, Murine-DerivedGenetic VectorsHistocompatibility TestingTransplantation Tolerance
ASCTTransplantMarrow transplantationHematopoietic cell transplantationChemotherapy and autologousCandidates for autologousBoneUnderwentPost-transplantationMelphalanRegimenRemissionPeripheral-bloodOutcomesHSCTImmunosuppressionMedian overall survivalImmunotherapyRelapse-freeNewly-diagnosed multiple myelomaPatient'sAutoHCTHaematopoieticTherapyRefractory diseaseRenalLymphomaUndergoClinicalSignificantlyImmuneKidneyDonorRelapsesDiagnosisMyelomaDisease-free survival ratesCytogeneticCellsPatientTumors
ASCT9
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) amyloidosis, but the benefit is debated mainly because of the high treatment-related mortality (24% in a randomised study comparing HDM/ASCT with oral melphalan/dexamethasone). (lu.se)
  • In conclusion, long survival times can be achieved in patients with AL amyloidosis treated with HDM/ASCT, also in smaller centres. (lu.se)
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. (cun.es)
  • Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). (wustl.edu)
  • At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. (nebraska.edu)
  • At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. (nebraska.edu)
  • In this ongoing Phase II multicenter study, 55 heavily pretreated patients with relapsed/refractory DLBCL, including almost 50% without a response to autologous stem cell transplantation (ASCT), were treated with fludarabine/cyclophosphamide lymphodepletion, followed by a dose of JCAR17. (medpagetoday.com)
Transplant15
  • Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. (elsevierpure.com)
  • With the increase in organ transplantation and improved survival of transplant recipients, the incidence of disease will likely increase in the coming years. (cdc.gov)
  • Median time from transplant to infection was 5 (range 2-54) for HSCT recipients and 28 (range 3-237) months for SOT recipients. (cdc.gov)
  • Researchers conducted a retrospective study on 136 transplant-eligible multiple myeloma patients from the national registry who underwent the first autologous stem cell transplantation between January 2018 and December 2021. (doctorsnewshubb.com)
  • Thanks to improved transplant survival rates, we have now been able to focus our efforts on examining how the procedure affects key aspects of recipients' overall quality of life, including sexual health," said lead study author F. Lennie Wong, PhD, of City of Hope in Duarte, California. (science20.com)
  • Data have been limited to this point, prompting us to take a closer look at this issue in a larger, more diverse group of autologous and allogeneic transplant survivors over an extended period. (science20.com)
  • Participants completed two questionnaires that together evaluated specific areas of sexual function (sexual cognition/fantasy, sexual arousal, sexual behavior/experience, orgasm, and drive/relationship) as well as sexual satisfaction at a median time of 17 days pre-transplant and at six, 12, 24, and 36 months post-transplant. (science20.com)
  • During the three-year post-transplant analysis period, the percentage of men who self-reported being "sexually active" (defined as having sex with a partner at least once in the preceding month) declined 7 percentage points, with 61 percent of men reporting sexual activity pre-transplant and 54 percent reporting activity post-transplant. (science20.com)
  • Because CHIP is associated with poorer prognosis in patients with non- Hodgkin lymphoma (NHL) and multiple myeloma (MM) who undergo autologous transplant, the researchers set out to determine if CHIP could influence outcomes in patients receiving CAR T-cell therapy. (cancertherapyadvisor.com)
  • My research focuses on ways to augment the immune system after an autologous transplant (where a patient's own blood-forming cells are harvested) to prevent relapse of disease and prolong survival. (fredhutch.org)
  • Short-term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. (ox.ac.uk)
  • In a Phase I clinical trial, 12 kidney transplant recipients received 1-10x106 Treg per kg at Day+5 post transplantation in lieu of induction immunosuppression (Treg Therapy cohort). (ox.ac.uk)
  • acute rejection-free survival was 100% in the Treg Therapy vs 78.9% in the reference cohort at 48 months post-transplant. (ox.ac.uk)
  • However, one-third of patients awaiting a kidney transplant are highly sensitized to human leukocyte antigens (HLA), resulting in an increased waiting time for a suitable kidney, more acute and chronic rejection, and a shorter graft survival compared to non-highly sensitised patients. (kcl.ac.uk)
  • Autologous polyclonally expanded regulatory T cells (Tregs) have been demonstrated to be safe in transplant settings and could be a potential alternative to modulate memory immune alloresponses. (kcl.ac.uk)
Marrow transplantation10
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Bone marrow transplantation , 37 (10), 929-935. (elsevierpure.com)
  • They further say that this study is one of the longest and is the most inclusive to date evaluating sexual well-being in blood or bone marrow transplantation (stem cell transplantation, SCT) survivors using rigorous, well-validated sexual function assessment tools. (science20.com)
  • As blood or bone marrow transplantation survival rates have steadily increased, researchers are seeking to study and maximize survivors' quality of life. (science20.com)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
Hematopoietic cell transplantation1
  • Introduction: In the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non-high-risk acute myeloid leukemia (AML) when allogeneic hematopoietic cell transplantation (alloHCT) is unfeasible, which is common in racial minorities because of donor registry under-representation and socioeconomic challenges. (elsevierpure.com)
Chemotherapy and autologous1
Candidates for autologous2
  • In a phase II trial reported in JAMA Oncology , Locke J. Bryan, MD , and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory classical Hodgkin lymphoma who were candidates for autologous stem cell transplantation (SCT). (ascopost.com)
  • 12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
Bone4
  • 1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
  • The procedure involves the transplantation of cells taken either from a patient's own blood or bone marrow (autologous transplantation) or from a matched donor (allogeneic transplantation) which effectively "replaces" damaged cells with healthy cells. (science20.com)
  • As a board-certified medical oncologist, I specialize in providing bone marrow transplantations to people with blood cancers. (fredhutch.org)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
Underwent3
  • Twenty-two patients underwent autologous or allogeneic stem cell transplantation (SCT). (bvsalud.org)
  • Thirty-six secondary progressive MS patients, among whom 21 were with OSMS and 15 with CMS, underwent APBSCT and were followed up for an average of 48.92Â months (range, 10-91Â months). (cellsurgicalnetwork.com)
  • Six patients underwent HSCT (5 allogeneic, 1 autologous) and 12 SOT (4 heart, 4 lung, 3 kidney, 1 liver). (cdc.gov)
Post-transplantation3
  • Here, we found that integrated Nrl.gfp(+ve) photoreceptors were present up to 12 months post-transplantation, albeit in significantly reduced numbers. (ox.ac.uk)
  • In a minority of eyes, we observed an early, marked reduction in integrated photoreceptors within 1 month post-transplantation, which correlated with increased numbers of amoeboid macrophages, indicating acute loss of transplanted cells due to an inflammatory response. (ox.ac.uk)
  • In the majority of transplants, similar numbers of integrated cells were observed between 1 and 2 months post-transplantation. (ox.ac.uk)
Melphalan3
Regimen2
Remission5
  • Multivariable analysis revealed that creatinine ≥2 mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. (scielo.br)
  • This phase III trial comparing idarubicin with high-dose daunorubicin as part of induction therapy in AML did not find significant differences in complete remission rates, relapse, or survival. (ascopost.com)
  • For patients with chronic myelomonocytic leukemia, the overall response rate was higher for azacitidine plus lenalidomide vs azacitidine alone (68% vs 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. (ascopost.com)
  • Interestingly, in one patient who relapsed after obtaining a CR following JCAR17 infusion, administration of a PD-1 inhibitor resulted in remission within 3 months, suggesting a potential resistance mechanism of immune escape which can be abrogated by PD-1 blockade. (medpagetoday.com)
  • Complete remission was achieved in 84% of dogs for a median of about 9 months. (vin.com)
Peripheral-blood4
Outcomes6
  • The aims of the present study were to describe clinical features at diagnosis, response to treatment and survival in 282 patients with active newly-diagnosed MM (NDMM) and compare outcomes between patients younger and older than 65 years. (scielo.br)
  • We compared outcomes of consolidation strategies in a minority-rich cohort in the Bronx with limited access to allogeneic transplantation. (elsevierpure.com)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • Our data suggest that CHIP can influence CAR T-cell biology and clinical outcomes, but, in contrast to autologous transplantation, CHIP was not associated with worse survival and should not be a reason to exclude individuals from receiving this potentially life-prolonging treatment," the researchers wrote. (cancertherapyadvisor.com)
  • Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate immunosuppression reduction promoting better long-term clinical outcomes. (ox.ac.uk)
  • Primary outcomes were rejection-free and patient survival. (ox.ac.uk)
HSCT8
  • Hematopoietic stem cell transplantation (HSCT) has been shown to be effective. (medscape.com)
  • In the prospective Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3 comparison of autologous HSCT with 12 successive monthly intravenous pulses of cyclophosphamide in 156 patients with early diffuse cutaneous systemic sclerosis, HCST was associated with higher treatment-related mortality than in the first year after treatment. (medscape.com)
  • Allogeneic and autologous HSCT recipients were matched to recipients of the same type. (cdc.gov)
  • Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
  • Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
  • According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
  • Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
  • Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
Immunosuppression4
  • In addition we also tested different immunosuppression regimens to demonstrate the feasibility and safety of the NHP EHM construct as well as the transplantation procedure. (ca.gov)
  • We have harvested the heart explants with the transplanted grafts as well as other organs from all transplanted animals and performed histological analysis to determine the effect of different immunosuppression regimens on graft survival and cell proliferation in vivo. (ca.gov)
  • The only curative treatment for ALF is liver transplantation, but there are many restrictions on the application of liver transplantation because of financial considerations, a shortage of donor livers, and immunosuppression-related complications [ 3 ]. (springer.com)
  • Autologous Treg therapy is feasible, safe and is potentially associated with a lower rejection rate than standard immunosuppression. (ox.ac.uk)
Median overall survival3
  • In patients with cardiac involvement or multiple organ involvement, survival was significantly shorter, median overall survival 49 and 56 months, respectively. (lu.se)
  • Median overall survival was 31.9 months for quizartinib versus 15.1 months for placebo. (medscape.com)
  • The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. (zdrowemiasto.pl)
Immunotherapy4
Relapse-free2
Newly-diagnosed multiple myeloma2
  • We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
  • The following is a summary of "Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients," published in the June 2023 issue of Hematology by Skerget et al. (doctorsnewshubb.com)
Patient's1
AutoHCT1
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Haematopoietic1
  • Background: Effectiveness of autologous haematopoietic stem-cell transplantation (AHSCT) in relapsing-remitting multiple sclerosis (MS) is well known, but in secondary-progressive (SP-) MS it is still controversial. (unifi.it)
Therapy7
  • Most data regarding the impact of age on survival mainly come from clinical trials developed before the current therapy choices were in use. (scielo.br)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)
  • The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. (elsevierpure.com)
  • Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. (ashpublications.org)
  • The study aimed to evaluate the short-term clinical effect, therapeutic response rate (TRR%), and therapy safety of a single intra-articular autologous MFAT injection for symptomatic knee OA. (mdpi.com)
Refractory disease1
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
Renal2
  • Renal involvement is common and impaired kidney function is associated with reduced median survival. (elsevierpure.com)
  • Autologous stem cell transplantation (SCT) for AL achieves superior response rates compared to chemotherapy alone but patients with end-stage renal disease (ESRD) may be excluded from consideration. (elsevierpure.com)
Lymphoma5
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • As stated by the investigators, "To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic[al] Hodgkin lymphoma in patients destined for an autologous SCT. (ascopost.com)
  • The investigators concluded, "Results suggest that the addition of pembrolizumab to ICE chemotherapy was well tolerated and highly effective in comparison with prior reports of chemotherapy-only regimens, supporting further investigation in patients with relapsed or refractory classic[al] Hodgkin lymphoma eligible for an autologous SCT. (ascopost.com)
  • Stem cell transplantation is an increasingly effective form of treatment for patients with blood cancer such as leukemia, lymphoma, and myeloma. (science20.com)
  • Untreated lymphoma progresses rapidly (1-2 months) from presentation to terminal stages. (vin.com)
Undergo1
  • The first 9 patients identified as being eligible in Part 1 will undergo baseline immune monitoring for 2 months to inform statistical analysis of the primary endpoint. (kcl.ac.uk)
Clinical4
  • The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure. (springer.com)
  • The Company has enough cash to further support its clinical progress through the next 18-24 months. (malaysiaglobalbusinessforum.com)
  • I divide my time between caring for patients - about five months out of the year - and conducting clinical trials, up to four or five at a time. (fredhutch.org)
  • With these six-year results, we are seeing remarkably sustained and durable clinical survival benefits with nivolumab plus ipilimumab year-over-year," said Solange Peters, M.D., Ph.D., professor and chair of medical oncology and the thoracic malignancies program in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. (advfn.com)
Significantly1
  • Immune suppression of recipients significantly increased transplanted photoreceptor survival, indicating that the loss observed in unsuppressed recipients resulted from T cell-mediated host immune responses. (ox.ac.uk)
Immune4
  • We identified a pre-transplantation immune phenotype suggesting a high risk of unsuccessful ex-vivo Treg expansion. (ox.ac.uk)
  • Long-term survival of photoreceptors transplanted into the adult murine neural retina requires immune modulation. (ox.ac.uk)
  • Macrophages and T cells were present around the transplantation site, indicating a chronic immune response. (ox.ac.uk)
  • These findings suggest that autologous donor cells are optimal for therapeutic approaches to repair the neural retina, though with immune suppression nonautologous donors may be effective. (ox.ac.uk)
Kidney2
Donor1
  • This experience supports the feasibility of sequential living donor KTx and autologous SCT for carefully selected patients with ESRD due to AL. (elsevierpure.com)
Relapses1
  • Kaplan-Meier and Cox analyses were used to estimate survival free from relapses (R-FS), disability progression (P-FS) and NEDA-2. (unifi.it)
Diagnosis3
  • Despite the fact that most follicular lymphomas are advanced at the time of diagnosis, many patients may not require treatment for prolonged periods of time, and the median survival of patients with follicular lymphomas has historically been approximately 8-10 years. (medscape.com)
  • [4] Five-year survival following diagnosis is approximately 83% in the United States. (wikipedia.org)
  • The median time from initial multiple myeloma diagnosis to sPCL was 31 months. (wustl.edu)
Myeloma3
Disease-free survival rates1
Cytogenetic1
Cells4
Patient2
  • The patient was a female in her 40s who had acute myeloid leukemia refractory to chemotherapy before progressing to cord blood transplantation. (bvsalud.org)
  • Controls received a similar organ within 3 months before or after the index case-patient at the same center and did not show Rhodococcus infection. (cdc.gov)
Tumors1